Shots:
- Kairos Pharma announced positive interim efficacy data from its ongoing P-II study evaluating ENV-105 (carotuximab) in combination with apalutamide in pts. with metastatic castration-resistant prostate cancer (mCRPC)
- The combination demonstrated a statistically significant improvement in progression-free survival, with median PFS of 17.7 mons. vs 2 mons. with apalutamide alone (P=0.0008)
- Following the interim results, Kairos Pharma modified the P-II protocol to enroll pts. earlier in disease progression, randomizing them to enzalutamide alone or enzalutamide plus ENV-105, with trial completion targeted in or before Q4’27
Ref: Business Wire | Image: Kairos Pharma | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information connect with us at connect@pharmashots.com
